VanEck Biotech ETF (NASDAQ:BBH) Stock Position Reduced by Peapack Gladstone Financial Corp

Peapack Gladstone Financial Corp trimmed its position in VanEck Biotech ETF (NASDAQ:BBH) by 10.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,510 shares of the company’s stock after selling 1,100 shares during the quarter. Peapack Gladstone Financial Corp owned approximately 0.39% of VanEck Biotech ETF worth $1,493,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Kovitz Investment Group Partners LLC raised its stake in VanEck Biotech ETF by 4.6% during the third quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock worth $565,000 after acquiring an additional 141 shares during the period. Farther Finance Advisors LLC bought a new position in shares of VanEck Biotech ETF during the fourth quarter valued at approximately $32,000. Flagship Harbor Advisors LLC raised its position in shares of VanEck Biotech ETF by 12.1% during the 4th quarter. Flagship Harbor Advisors LLC now owns 1,984 shares of the company’s stock worth $311,000 after purchasing an additional 214 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of VanEck Biotech ETF in the 4th quarter worth approximately $81,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in VanEck Biotech ETF during the 3rd quarter valued at approximately $166,000. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Price Performance

Shares of BBH opened at $140.10 on Wednesday. The company has a market cap of $326.43 million, a P/E ratio of 29.88 and a beta of 0.85. VanEck Biotech ETF has a 12 month low of $138.40 and a 12 month high of $183.64. The stock has a fifty day moving average price of $160.82 and a 200 day moving average price of $164.77.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.